- Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Conditions: Astigmatism; Myopia
Interventions: Device: senofilcon A; Device: etafilcon A; Device: nelfilcon A; Device: Filcon II 3; Device: Filcon II 3
Sponsors: Vistakon; Vistakon
Not yet recruiting - verified May 2012 - Condition: Basal Cell Carcinoma
Intervention: Other: OCT
Sponsors: Maidstone & Tunbridge Wells NHS Trust; Maidstone & Tunbridge Wells NHS Trust
Not yet recruiting - verified May 2012 - Condition: Ocular Allergy
Interventions: Other: Non-Pharmaceutical Tear Supplement; Device: Eye Gel Mask Blue placed over the closed eyes; Drug: ELESTAT® (epinastine HCl ophthalmic solution) 0.05%
Sponsors: Aston University; Aston University; National Pollen and Aerobiology Research Unit, University of Worcester
Recruiting - verified April 2012 - Conditions: Uveitis Related Cystoid Macular Edema; Steroid-induced Glaucoma - Borderline
Intervention: Drug: Ranibizumab
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Novartis
Recruiting - verified March 2012 - Condition: Metastatic Uveal Melanoma
Interventions: Drug: Dacarbazine; Drug: Sunitinib
Sponsors: Clatterbridge Centre for Oncology NHS Foundation Trust; Clatterbridge Centre for Oncology NHS Foundation Trust; Cancer Research UK; Pfizer
Recruiting - verified March 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Contact Lens Related Dry Eye Syndrome
Interventions: Device: OPTIVEtm Plus; Procedure: No treatment; Device: Blink Contacts® Eye Drops
Sponsors: Optometric Technology Group Ltd; Optometric Technology Group Ltd; Allergan
Recruiting - verified February 2012 - Conditions: Retinal Vein Occlusion; Macular Edema; Uveitis, Posterior
Intervention: Drug: dexamethasone 700 μg intravitreal implant
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Condition: Retinal Diseases
Interventions: Drug: GW824575; Drug: GW824575 matched-placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: LCA (Leber Congenital Amaurosis); RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
Sponsors: QLT Inc.; QLT Inc.
Recruiting - verified May 2012 - Conditions: No Condition; Brain GABA-B Function
Interventions: Drug: Baclofen 10mg; Drug: Baclofen 60mg; Drug: placebo
Sponsors: Imperial College London; Imperial College London; Medical Research Council
Not yet recruiting - verified March 2012 - Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseCondition: Advanced Idiopathic Parkinson's Disease
Interventions: Other: Placebo; Other: Rotigotine
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Age Related Macular Degeneration (ARMD)
Interventions: Behavioral: Supervised Reading; Behavioral: EVT at the PRL; Behavioral: EVT at the TRL
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; British Eye Research Foundation, operating as Fight for Sight
Recruiting - verified December 2011 - Condition: Macular Edema
Interventions: Drug: dexamethasone Intravitreal Implant; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Stargardt's Macular Dystrophy; Fundus Flavimaculatus; Juvenile Macular Dystrophy
Intervention: Biological: Biological: MA09-hRPE Cellular therapy
Sponsors: Advanced Cell Technology; Advanced Cell Technology
Recruiting - verified January 2012 - Condition: Choroideremia
Intervention: Drug: rAAV2.REP1
Sponsors: University of Oxford; University of Oxford; Oxford University Hospitals NHS Trust; Moorfields Eye Hospital NHS Foundation Trust; University College, London; Central Manchester University Hospitals NHS Foundation Trust; University of Manchester; Southampton University Hospitals NHS Trust; University of Southampton
Recruiting - verified October 2011 - Conditions: Optic Neuritis; Multiple Sclerosis
Interventions: Drug: Phenytoin; Drug: Placebo
Sponsors: University College, London; University College, London; National Multiple Sclerosis Society; Multiple Sclerosis Society of Great Britain and Northern Ireland
Not yet recruiting - verified October 2011 - Condition: HIV
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Condition: Uveal Melanoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: dexamethasone intravitreal implant (Ozurdex®); Biological: ranibizumab (Lucentis®)
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Condition: Glaucoma
Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Condition: Keratoconus
Interventions: Procedure: Artemis Ultrasound Exam; Procedure: ARFI Ultrasound exam
Sponsors: Columbia University; Columbia University; National Eye Institute (NEI)
Recruiting - verified February 2012 - Condition: Dry Eye
Interventions: Drug: Next Generation Emulsion; Drug: Refresh Dry Eye Therapy; Drug: Refresh Contacts
Sponsors: Glasgow Caledonian University; Glasgow Caledonian University; Allergan
Not yet recruiting - verified February 2011 - Condition: Proliferative Diabetic Retinopathy
Intervention: Procedure: Pan retinal Photocoagulation
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Insulin Dependant Diabetes Trust
Not yet recruiting - verified June 2011 - Conditions: Migraine; Cluster Headache; Control; Menstrual Migraine
Intervention:
Sponsors: University College London Hospitals; University College London Hospitals
Not yet recruiting - verified May 2011 - Condition: Uvea; Posterior, Disorder
Interventions: Drug: DE-109; Drug: DE-109; Drug: DE-109
Sponsors: Santen Inc.; Santen Inc.
Recruiting - verified June 2011 - Condition: Type 2 Diabetes
Intervention: Biological: Glycaemic optimisation before surgery
Sponsors: Imperial College London; Imperial College London
Recruiting - verified January 2012 - Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Intervention: Other: Ranibizumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Conditions: Diabetic Retinopathy; Retinal Neovascularisation
Interventions: Drug: Ranibizumab; Drug: Saline
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Novartis
Recruiting - verified May 2011 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Other: No intervention other than routine medical care; Other: No intervention other than routine medical care
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Diabetic Retinopathy; Macular Oedema
Intervention: Drug: Ranibizumab
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes Mellitus; Obesity; Bariatric Surgery
Intervention: Drug: Insulin
Sponsors: Imperial College London; Imperial College London
Recruiting - verified January 2012 - Condition: Cardiac Iron Overload
Intervention: Drug: Deferasirox and Deferoxamine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Raised Intraocular Pressure
Interventions: Drug: AZD4017; Drug: Placebo; Drug: AZD4017; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Conditions: Anti- VGF Inhibitor; Diabetic Macular Edema; Diabetic Retinopathy
Intervention: Drug: pega
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Diabetes Complications
Interventions: Drug: Ranibizumab; Drug: 0.9% Sodium Chloride
Sponsors: King's College Hospital NHS Trust; King's College Hospital NHS Trust; Novartis
Recruiting - verified February 2011 - Conditions: Retinitis Pigmentosa; Retinal Degeneration
Intervention: Device: Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye
Sponsors: Retina Implant AG; Retina Implant AG
Recruiting - verified December 2011 - Conditions: LCA (Leber Congenital Amaurosis); RP (Retinitis Pigmentosa)
Intervention: Drug: QLT091001
Sponsors: QLT Inc.; QLT Inc.
Recruiting - verified April 2012 - Conditions: Purpura, Thrombocytopenic, Idiopathic; Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAIONCondition: Optic Neuropathy, Ischemic
Intervention: Drug: No intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
 |
Join Clinical Trials in Aberdeen, Idaho |
